PharmTech Drug Digest 11.20

All News


ePT--the Electronic Newsletter of Pharmaceutical Technology

In an effort to standardize quality agreements for active pharmaceutical ingredients in the drug industry, the Bulk Pharmaceuticals Task Force, an affiliate of the Society of Chemical Manufacturers and Affiliates, has developed a template to help manufacturers and customers comply with US regulatory requirements in a simplified manner.

ePT--the Electronic Newsletter of Pharmaceutical Technology

The European Ombudsman has recommended that the European Medicines Agency review its refusal to grant public access to reports on adverse drug reactions.

Pharmaceutical Technology Europe

In response to stringent price cuts introduced in Spain, the European Generics Association (EGA) is urging the Spanish government to adopt mechanisms that will help increase the dispensing of generic medicines.

ePT--the Electronic Newsletter of Pharmaceutical Technology

The year 2016 will see Pfizer barely continue to cling to first place on the Top 10 pharma list, with Merck & Co. and Novartis not far behind.

Mixed Blessings

When vessels, seals, and cooling units go haywire, operators must get in the mix.

i1-667248-1408638328533.jpg

What do you think?

Pharmaceutical Technology Europe

Over the last few months, we have been publishing a series of special features, which have sought to provide you with an overall view of current challenges, innovations and trends in niche pockets of the pharmaceutical industry.

Pharmaceutical Technology Europe

A new automated factory in Boston (MA, USA) has been developed that uses non-genetically modified green plants to quickly produce large quantities of vaccines and therapeutics.

ePT--the Electronic Newsletter of Pharmaceutical Technology

The European Medicines Agency published a summary report that includes suggestions for improving the current processes for evaluating benefit-risk.

Pharmaceutical Technology Europe

An evaluation conducted by Ernst & Young assessing the effectiveness and efficiency of the European Medicines Agency has largely praised the agency; however, a number of strategic and operational recommendations for further improvements have also been made.